Atherosclerosis and Osteoporosis. Common Targets for the Effects of Cardiovascular and Anti-osteoporotic Drugs (Part I). The Effect of Cardiovascular Drugs on Bone Strength

Скрипникова, И. А.; Alikhanova, Natavan; Kolchina, M. A.; Myagkova, M.A.; Косматова, О. В.

doi:10.20996/1819-6446-2019-15-1-69-76

Cited by 2 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, evidence shows a difference in bone cell penetration in patients on different statin groups (lipophilic and hydrophilic statin groups) ( Skripnikova et al, 2019 ; Rejnmark et al, 2006 ; Shahrezaee et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis

et al. 2022

View full text Add to dashboard Cite

Objectives The correlation between atherosclerosis and osteoporosis, independent of age, is clear. Multifactorial co-dependence between bone mineral density (BMD) and statin dose has been proposed. It is hypothesised that inhibition of the synthesis of cholesterol will also inhibit the synthesis of sex hormones and Vitamin D, negatively affecting BMD. This study aims to evaluate hydrophilic and non-hydrophilic statins effect on osteoporosis and analyse any possible superiority of one agent over the other within the group. Methods We identified 538 caucasian females who had a DEXA scan performed between 2002 and 2016 (age 60–89) in one DEXA center in Mid-West Ireland. A DEXA T-score results were analysed in the current study. Two hundred fifty females were not on statin therapy, and 323 females were on statin therapy. Females on therapy were separated into the atorvastatin group ( N = 190), rosuvastatin group ( N = 97), and pravastatin group ( N = 36), comprising low dose and high dose groups. All anonymised data were analysed with SPSS statistical. To test the hypothesis that lower bone density is associated with high dose statins, an independent sample t -test was performed. The one-way between-groups ANOVA test was used to test the hypothesis that the BMD level depended on the statin's potency. Results Statin-naïve females have a statistically higher bone mineral density in the lumbar spine, t (538) = 3.42, p < 0.05 and in hip t (538) = 4.99, p < 0.05 than females on statin therapy. There was a significant difference in patient's age between the group, and no significant correlation was found between the patient's age and type of statin or bone density. In the atorvastatin group statistically, significant results were obtained both for spine and hip bone mineral density, t (188) = −5.61, p < 0.05 and t (188) = −3.62, p < 0.05, respectively. In the rosuvastatin group, statistically, a significant result was noted for bone mineral density of hip t (95) = −3.52, p < 0.05. This demonstrates a dose-dependency between bone mineral density and the dose of the statin. The independent between-group ANOVA yielded a statistically significant effect, F (2, 59) = 6.69, p < 0.05, η2 = 0.21 in the spine. Thus, patients on lipophilic statins had statistically lower BMD than females on hydrophilic statins. Multilinear regression analysis identified that age is not a statistically significant contributor in our analysis; however, the trend of decrease in bone mineral density with women's age is acknowledged by authors. Conclusions The study results support the theory that bone mineral density decreases with an increase in a statin dose, and hydrophilic statins, like pravastatin, have a better metabolic profile in the lumbar spine than lipop...

show abstract

Section: Introductionmentioning

confidence: 99%

Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis

et al. 2022

View full text Add to dashboard Cite

show abstract

Modern genetic and immunological aspects of the pathogenesis of impaired consolidation of fractures (literature review)

Мироманов

Gusev

Staroselnikov

et al. 2022

Acta biomedica scientifica

View full text Add to dashboard Cite

The aim of this article is to analyze the genetic and immunological mechanisms of the development of fracture consolidation disorders at the present scientific stage.Materials and methods. The search for literary sources was carried out in the open electronic databases of scientific literature PubMed and eLIBRARY. Search depth – 10 years.Results. The review analyzes the literature data on the current state of the study of the molecular genetic mechanisms of reparative regeneration including the development of fracture consolidation disorders. The mechanisms of the most important links of pathogenesis which most often lead to various violations of the processes of bone tissue repair are considered.Conclusion. The process of bone tissue repair is multifaceted, and many factors are involved in its implementation, however, we would like to note that the leading role in the course of reparative regeneration is played by a personalized genetically programmed response to this pathological condition. Nevertheless, despite the undeniable progress of modern medicine in studying the processes of bone recovery after a fracture, there are still many “white” spots in this issue, which dictates the need for further comprehensive study in order to effectively treat patients with impaired consolidation.

show abstract

Atherosclerosis and Osteoporosis. Common Targets for the Effects of Cardiovascular and Anti-osteoporotic Drugs (Part I). The Effect of Cardiovascular Drugs on Bone Strength

Cited by 2 publications

References 58 publications

Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis

Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis

Modern genetic and immunological aspects of the pathogenesis of impaired consolidation of fractures (literature review)

Contact Info

Product

Resources

About